An Analysis on HCV Treatment Efficacy among HIV/HCV Co-infected Patients

Gu Shan Qun; Li Zhong Xi; Bai Jing Song; Tian Bo; Yu Min; Liu Jun

Volume 39 Issue 05

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2018 > 39(05): 120-123

Gu Shan Qun , Li Zhong Xi , Bai Jing Song , Tian Bo , Yu Min , Liu Jun . An Analysis on HCV Treatment Efficacy among HIV/HCV Co-infected Patients[J]. Journal of Kunming Medical University, 2018, 39(05): 120-123.

Citation:

Gu Shan Qun , Li Zhong Xi , Bai Jing Song , Tian Bo , Yu Min , Liu Jun . An Analysis on HCV Treatment Efficacy among HIV/HCV Co-infected Patients[J]. Journal of Kunming Medical University, 2018, 39(05): 120-123.

Citation:

PDF( 188 KB)

An Analysis on HCV Treatment Efficacy among HIV/HCV Co-infected Patients

Funds:

基金：云南省教育厅科学研究基金资助项目 (2017ZDX011);

Received Date: 2018-02-03

Abstract

Abstract

Objective To observe the efficacy and safety of DAAs in treating HCV patients with HIV/HCV co-infection.Me thod 53 patients were divided into groups based on HCV genotype. Sofosbuvir + Ledipasvir regime were used for 1 b and 6 a subtypes; sofosbuvir + Daclatasvir regime were used for 3 a, 3 b and those cannot be typed; all the patients diagnosed with cirrhosis were also administrated with ribavirin. The course of treatment for all patients is 12 weeks.Re s ults All 53 patients completed HCV treatment, the overall SVR rate of DAAs treatment rate was 98.1% (52/53) , failure rate 1.9% (1/53) ; SVR rate of DAAs treatment among non-cirrhosis patients was 100% (41/41) ; SVR rate of DAAs treatment among cirrhosis patients was 91.7% (11/12) , failure rate8.3% (1/11) . After treatment, ALT and AST levels of DAAs treatment patients were decreased (P<0.05) , while CD4 level increased (P <0.05) . Main adverse effects are: 12 patients had gastrointestinal symptoms (22.6%) ; 6 had nausea, vomiting (11.3%) , 4 had diarrhea (7.6%) , 1 had mild rash (1.9%) , and 5 had elevated serum total bilirubin (9.4%) . Conclus ion The overall SVR rate among DAA treatment for HIV/HCV co-infected patients is high (98.1%) with broad indications. Even patients with cirrhosis are eligible. It yielded optimistic outcomes among different gene subtypes, and effectively improved liver function and CD4 level. With oral administration, short regime course, and mild adverse effects, patients can tolerate well, indicating its effectiveness and safety.
- HIV/HCV co-infection,
- DAAs,
- HCV,
- Treatment

FullText(HTML)

References(14)

References

[1]	[1] MARK S, SULKOWSKI MD, DAVID L, et nl.Hepatitis C in the HIV in fected person[J].Annals of Internal Medicine, 2003, 138 (3) :197-208.
[2]	[2]KANG L, HU J, XIA X S, et a1.HIV and HCV:from Co-infection to epidemiology, transmission, pathogenesis, and treatment[J].Virologica Sinica, 2007, 22 (6) :443-450.
[3]陈圆生, 李黎, 崔富强, 等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志, 2011, 32 (9) :888-891.
[4]	[4]IRENAM AIER, GEORGE YW.Hepatitis C and H IV Co-infection:A Review[J].World J Gastroentero, 2002, 8 (4) :577-579.
[5] 闰宇翔, 马子寅, 高艳清.HIV感染者中HBV/HCV混合感染情况及危险因素分析[A].首都医科大学公共卫生与家庭医学学院2010年第四届学术年会, 2010:62-68.
[6]阴宁, 梅珊, 张林琦, 等HIV感染者中HCV混合感染情况分析[J].中国抗感染化疗杂志, 2002, 2 (2) :67-69.
[7]马建新, 王江蓉, 沈银忠, 等.上海地区人类免疫缺陷病毒/艾滋病合并乙型丙型肝炎病毒感染的流行病学研究[J].微生物与感染, 2006, 04 (1) :207-210.
[8]刘俊, 陶剑, 田波, 等.昆明地区丙型肝炎病毒感染者与HIV合并丙型肝炎病毒感染者肝损伤研究.中国病毒病杂志, 2014, 4 (1) :26-28.
[9]	[9]EUROPEAN ASSOCIATION FOR STUDY OF LIVER.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol, 2015, 63 (1) :199-236.
[10]	[10]AASLD/IDSA HCV Guidance Panel.Hepatitis C guidance:AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.
[11]	[11]HJERRILD S, DALGARD O, CHRISTENSEN P B, et al.Debilitating fatigue as a treatment indicatioin chronic hepatitis C[J].J Hepatol, 2015, 63 (6) :1533-1534.
[12]	[12] NAGGIE S, COOPER C, SAAG M, et al.Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1[J].N Engl J Med, 2015, 373 (8) :705-713.
[13]	[13] SULKOWSKI M S, ERON J J, WYLES D, et al.Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1:a randomized trial[J].JAMA, 2015, 313 (12) :1223-1231.
[14]周文劲, 刘俊, 白劲松, 等.HIV/HCV共感染者肝穿病理与临床指标[J].昆明医科大学学报, 2017, 38 (6) :136-139.

Relative Articles(20)

Relative Articles

[1]	Xiaoyan WANG, Ya LI, Chenglu HE, Lin WANG, Zhiqiang MA, Xinrui WAN. Study on Immune Function and Drug Resistance of Tuberculosis Patients Co-infected with HBV，HCV and HIV in Yunnan. Journal of Kunming Medical University, 2023, 44(12): 51-58. doi: 10.12259/j.issn.2095-610X.S20231209
[2]	Xi-hua ZHANG, Tao JIA, Wei-tao LIU, Qing WAN, Jin-feng WANG, Xi LI, Jin-song LIU. The Pathogenesis and Current Therapy of Hip Ankylosis. Journal of Kunming Medical University, 2021, 42(9): 144-148. doi: 10.12259/j.issn.2095-610X.S20210902
[3]	Tian Bo , He Li Ping , Liu Jun , Li Zhong Xi , Bai Jing Song , Gu Shan Qun . . Journal of Kunming Medical University, 2020, 41(02): 163-167.
[4]	Yang Yong Rui , Shen Ling , Wu Wen Long , Guo Ying Wu , Li Hai Wen , Liu Jun , Li Xiao Fei . . Journal of Kunming Medical University, 2020, 41(09): 107-113.
[5]	Zhong Min , Li Ya , He Zeng Pin , Zhang Hui , Duan Yong . . Journal of Kunming Medical University, 2019, 40(04): 126-130.
[6]	Li Zhong Xi , Bai Jing Song , Tian Bo , Zhou Wen Jing , Liu Jun . . Journal of Kunming Medical University, 2019, 40(07): 100-105.
[7]	Li Zhong Xi , Liu Jun , Bai Jing Song , Yu Min , Gao Cheng Bing . . Journal of Kunming Medical University, 2018, 39(12): 103-107.
[8]	Zhou Wen Jing , Liu Jun , Bai Jing Song , Tian Bo , Jin Yong Mei , Tao Jian , Li Zhong Xi , Chen Jian Hua . Correlation between Hepatic Pathohistology of Biopsies and Clinical Indices in Patients with HIV/HCV Co-infection. Journal of Kunming Medical University, 2017, 38(06): 136-139.
[9]	Li Ming . The Current Situation of Research and Treatment on Male Breast Cancer. Journal of Kunming Medical University,
[10]	Yuan Hua Yuan . . Journal of Kunming Medical University,
[11]	Zhang Yong Chun . . Journal of Kunming Medical University,
[12]	Lan Qing . . Journal of Kunming Medical University,
[13]	Zhang Meng Si . . Journal of Kunming Medical University,
[14]	Zhang Yi . . Journal of Kunming Medical University,
[15]	Fang Ke Wei . . Journal of Kunming Medical University,
[16]	Yan Bing . . Journal of Kunming Medical University,
[17]	Li Xian Li . . Journal of Kunming Medical University,
[18]	Zhan Hui . Treating Complex Upper Urinary Calculi With Different Type of Channel of Percutaneous Renal Fistula. Journal of Kunming Medical University,
[19]	Liu Jun . Comparison of Liver Function in Patients with HIV/HCV Coinfection at Different CD4 T Cell Count Level in Kunming. Journal of Kunming Medical University,
[20]	Liu Wen Feng . . Journal of Kunming Medical University,

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	张宪基，汪宗保，王科文，李鑫，李德坤，单自亮，姚长风. 艾灸对膝骨关节炎兔软骨Wnt信号通路及血清炎性因子的影响. 江苏中医药. 2023(12): 68-72 .
2.	杨萍. 中药影响膝骨关节炎信号通路的研究进展. 风湿病与关节炎. 2022(12): 71-75 .
3.	兰维娅，唐芳，马武开，姚血明，卢向阳，周静，陈琳英，李宇. 基于经典Wnt/β-catein信号通路的中医药干预膝骨关节炎的研究述评. 风湿病与关节炎. 2018(03): 66-69 .
4.	桂向洪，陈晔. 膝骨关节炎患者滑膜组织中β-catenin及MMP-3表达水平研究. 国际检验医学杂志. 2017(20): 2931-2932+2940 .
5.	李龙滕，李彦林，王坤，肖渝，闫祥甲. 信号通路在骨性关节炎发病中的作用. 昆明医科大学学报. 2017(04): 137-141 . 本站查看
6.	万美珍，邓紫玉，代龙金. 独活寄生汤治疗肝肾不足型膝骨关节炎的临床疗效观察. 中国社区医师. 2017(14): 92-93 .